MeDICAL ADVOCATES
Older Persons and HIV
  Antiretroviral Drugs

ARVs- General Reports
 Efavirenz
 Darunavir
 Raltegravir
 Tenofovir Emtricitabine 

 


 
Older Main Page Main New/Newsworthy  Home Page
Last Update:  May 05, 2017
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
ARVs: General
     
          Journal Papers, Abstracts, and Commentaries
 
 
The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development.
Smith JM, Flexner C.
AIDS. 2017 Jun 1;31 Suppl 2:S173-S184.
 Abstract

FULL-TEXT  ARTICLE
Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients.
 Kowalska JD, Kubicka J, Siwak E, et al
AIDS Res Ther. 2016 Jan 7;13:2.
Paper

Antiretroviral Treatment Efficacy and Safety in Older HIV-Infected Adults.
Jourjy J, Dahl K, Huesgen E.
Pharmacotherapy. 2015 Dec;35(12):1140-51
 Abstract

Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection.
Winston A, Underwood J.
Curr Opin Infect Dis. 2014 Nov 6.
Abstract

Psychosocial burdens negatively impact HIV antiretroviral adherence in gay, bisexual, and other men who have sex with men aged 50 and older
Halkitis PN, Perez-Figueroa RE, Carreiro T, et al
AIDS Care. 2014 May 27:
 Abstract

Morbidity in Older HIV-Infected Patients: Impact of Long-Term Antiretroviral Use.
Guaraldi G, Prakash M, Moecklinghoff C, Stellbrink HJ
AIDS Rev. 2014 Apr 24;16(2).
Abstract

Aging and HIV/AIDS: pathogenetic role of therapeutic side effects.
Torres RA, Lewis W.
Lab Invest. 2013 Dec 16.
 Abstract

Clinical pharmacokinetics of antiretroviral drugs in older persons.
Schoen JC, Erlandson KM, Anderson PL.
Expert Opin Drug Metab Toxicol. 2013 Mar 20.
 Abstract

Optimal antiretroviral therapy for aging.
Cordery DV, Cooper DA.
Sex Health. 2011 Nov;8(4):534-40.
 Abstract

Aging with HIV: medication use and risk for potential drug-drug interactions.
Marzolini C, Back D, Weber R, et al
 J Antimicrob Chemother. 2011 Jun 16.
 Abstract

Predicting Adherence to Antiretroviral Therapy in HIV-Infected Older Adults:
The Moderating Role of Gender.
Bianco JA, Heckman TG, Sutton M,  et al
AIDS Behav. 2010 Jul 15.
 Abstract
Darunavir
     

          Journal Papers, Abstracts, and Commentaries

  Treating Older HIV-1-infected Subjects with Cobicistat-boosted Darunavir in a 48-Week Phase 3 Trial.
Brown K, Patterson-Browning B, Liu C, et al
Rev Recent Clin Trials. 2017 Apr 7.
 Abstract

Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
Calza L, Colangeli V, Magistrelli E, et al
HIV Med. 2017 Jan 24.
Abstract
Efavirenz
     

          Journal Papers, Abstracts, and Commentaries

  Outcomes In Older Versus Younger Patients Over 96 Weeks In Hiv-1-Infected Patients Treated With Rilpivirine Or Efavirenz In Echo And Thrive
Ryan R, Dayaram YK, Schaible D,  et al
Curr HIV Res. 2014 Jan 28
 Abstract
Raltegravir
     

          Journal Papers, Abstracts, and Commentaries

  Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
Calza L, Colangeli V, Magistrelli E, et al
HIV Med. 2017 Jan 24.
Abstract

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera JH, Jackson A, Dickinson L, et al
 HIV Clin Trials. 2015 Jan-Feb;16(1):39-42.
Abstract

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals.
Singh GJ, Jackson A, D'Avolio A, et al  
AIDS. 2014 Aug 24;28(13):1993-5.
 Abstract
Tenofovir Emtricitabine
     

          Journal Papers, Abstracts, and Commentaries

  Risks and benefits of HIV pre exposure prophylaxis with tenofovir/emtricitabine in an older man with co-morbidities.
Girometti N, Jones R, Levy J, et al   
AIDS. 2016 May 21
 Abstract

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
 Pedrol E, Caro-Murillo AM, et al
 HIV Clin Trials. 2015 Jan-Feb;16(1):43-8. 
Abstract

 

Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in Spain: The TRIP Study.
 Blanco JR, Caro-Murillo AM, Castaņo MA,  et al
HIV Clin Trials. 2013 Sep-Oct;14(5):204-15.
Paper

Older Main Page Main New/Newsworthy  Home Page

Older Persons and HIV
Antiretroviral Drugs